nivolumab,relatlimab,ipilimumab
bms
['047 ,(-nct047),(-0.047%),(-2047)', 'relativity,047', 'melanoma']
 presents updates of relativity-047 at #melanoma session at #asco23. it has been hard for me to figure out where to fit this regimen in 1l setting. 1/ 
Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.